China Pharma Holdings, Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023; comparative period is Q1 2022. The company develops, manufactures and markets pharmaceutical products in China. Figures below are in U.S. dollars unless stated otherwise.
Financial performance
| Metric | Q1 2023 | Q1 2022 |
|---|---|---|
| Revenue | $1.960 million | $1.604 million |
| Gross profit (loss) / margin | $178,000 / 9.1% | $(169,000) / (10.6%) |
| Operating loss | $(397,000) | $(912,000) |
| Net loss | $(476,000) | $(1.029) million |
| Loss per share, basic and diluted | $(0.06) | $(0.22) |
| Cash used in operating activities | $(1.468) million | $(879,000) |
| Cash flows from financing activities | $518,000 provided | $276,000 used |
| Cash and cash equivalents at period end | $1.167 million | $2.030 million at Dec. 31, 2022 |
Revenue rose 22.2%, which management attributed mainly to market recovery after China eased pandemic controls. Revenue growth and lower operating expenses helped reduce losses, although the company remained loss-making. Cost of revenue was 90.9% of revenue, versus 110.6% a year earlier. Interest expense was $79,000, compared with $124,000.
Q1 cash declined by $863,000. Investing cash flow is reported as $55,964 provided in the cash flow statement, although MD&A describes $55,964 as used; the filing text is inconsistent on this item.
Balance sheet, debt and liquidity
- At March 31, 2023, total assets were $17.356 million, total liabilities $12.687 million, and stockholders’ equity $4.669 million. Current assets were $6.081 million against current liabilities of $11.922 million.
- Current debt included $2.983 million of lines of credit, $2.497 million of related-party borrowings, and a $3.150 million convertible, redeemable note. The company had no remaining availability on its approximately $1.0 million credit line drawn in full; other facilities were due in September and December 2023.
- The CEO/chair personally guaranteed certain bank facilities. Related-party advances from the CEO were $1.143 million; a separate board-member advance was $1.355 million.
- Net trade receivables were $549,000, against a doubtful-account allowance of $16.956 million. The filing says 96.78% of receivables were more than 720 days old. Inventory increased to $3.760 million from $2.948 million at year-end.
- Management disclosed substantial doubt about the company’s ability to continue as a going concern within one year after issuance. Cash was $1.2 million, and management cited continuing expected operating losses and debt-service costs. The cash was held in the PRC subsidiary and was not expected to be available for parent-company or shareholder payments.
Material changes, outlook and risks
- Product-category revenue increased in CNS/cerebral and cardiovascular products, digestive disease products and “Other,” while anti-viral/infection and respiratory revenue declined. Mask sales contributed to “Other” growth. The company’s largest category remained anti-viral/infection and respiratory at 51% of revenue.
- Management plans to increase advance payments and strengthen receivable collections, and is exploring strategic alternatives to accelerate nutrition-product launches. It also believes fixed assets may support additional bank borrowing. These plans were not finalized; management stated there can be no assurance they will succeed. No quantified financial guidance was provided.
- The convertible note matured February 17, 2023. On April 13, 2023, the investor and company extended maturity to May 19, 2024. The company added a $65,639 extension fee to the note balance, reduced the conversion price from 85% to 82% of a specified volume-weighted average price, and accepted monthly redemption obligations or additional penalties. The note’s conversion/redemption mechanism may cause substantial share dilution.
- After quarter-end, the investor converted/redemptions of $200,000 and $150,000 of note principal and related interest into 712,250 and 567,322 shares, respectively. The company also completed a 1-for-10 reverse stock split effective March 6, 2023; reported share figures were retroactively adjusted.
- Key operating and regulatory risks include China’s generic-drug consistency evaluations and centralized procurement, which can require investment while lowering drug prices; PRC currency conversion and remittance controls; foreign-exchange exposure; and possible future COVID-19 disruptions. Three customers represented 52.6%, 11.3% and 10.3% of receivables at quarter-end.
- Disclosure controls were assessed as ineffective because of a material weakness related to insufficient U.S. GAAP-qualified accounting and financial-reporting personnel. Management nevertheless concluded the interim financial statements were fairly stated in all material respects.
Important facts for investors to verify
- Whether management can fund operations and address the explicitly disclosed going-concern doubt, including whether additional financing or strategic alternatives are finalized.
- The convertible note’s post-amendment balance, redemption schedule, penalties and potential dilution, along with the status and terms of maturing bank facilities.
- Recoverability of aged receivables and inventory, and whether reported collections support management’s collection plans.
- Progress and economics of product consistency evaluations, centralized procurement participation, and proposed nutrition-product launches.
- Resolution of the cash-flow MD&A inconsistency and remediation of the material weakness in financial-reporting controls.